Stratum Receives OK to Begin Artinia Heart Health Study
Stratum Nutrition (St. Louis, MO) has announced that the company, in collaboration with its European partner KitoZyme (Herstal, Belgium), will soon begin a six-week human clinical study on Artinia, a chitin-glucan fiber marketed for heart health.
Stratum Nutrition (St. Louis, MO) has announced that the company, in collaboration with its European partner KitoZyme (Herstal, Belgium), will soon begin a six-week human clinical study on Artinia, a chitin-glucan fiber marketed for heart health.
Thus far, a 12-week animal and 30-day human pilot study have been performed on the ingredient. The upcoming study, which has received approval frmo an Institutional Review Board, will be randomized, double-blind, and placebo-controlled at three clinical sites. Biomarkers to be measured will include the oxidation of low-density lipoprotein (LDL or 'bad'ÃÂ cholesterol), lipids, insulin, and other markers related to inflammation and human safety.
The study is expected to be completed by the end of this year. For more information on the ingredient, visit Stratum Nutrition here.
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.
